Download Free Sample Report

Follicular Lymphoma Drugs Market, Global Outlook and Forecast 2023-2029

Follicular Lymphoma Drugs Market, Global Outlook and Forecast 2023-2029

  • Published on : 31 March 2023
  • Pages :69
  • Report Code:SMR-7622826

Download Report PDF Instantly

Leave This Empty:

Secure

Report overview

Follicular lymphoma is a cancer that affects white blood cells called lymphocytes. There are two types of lymphomas: Hodgkin's and non-Hodgkin's, based on the kind of white blood cell they affect. Follicular lymphoma is a non-Hodgkin's lymphoma.Drugs for Follicular lymphoma are Anti-CD20 mAbs, Chemotherapy Agents, Kinase Inhibitor, etc.
This report aims to provide a comprehensive presentation of the global market for Follicular Lymphoma Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Follicular Lymphoma Drugs. This report contains market size and forecasts of Follicular Lymphoma Drugs in global, including the following market information:
Global Follicular Lymphoma Drugs Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Follicular Lymphoma Drugs market was valued at US$ 1760.6 million in 2022 and is projected to reach US$ 2842.4 million by 2029, at a CAGR of 7.1% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Global core follicular lymphoma drugs players include Roche, Teva and Bayer etc. The Top3 companies hold a share about 57%. North America is the largest market, with a share about 58%, followed by Europe and Asia Pacific with the share about 21% and 20%.
We surveyed the Follicular Lymphoma Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Follicular Lymphoma Drugs Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Follicular Lymphoma Drugs Market Segment Percentages, by Type, 2022 (%)
Anti-CD20 mAbs
Chemotherapy Agents
Kinase Inhibitor
Others
Global Follicular Lymphoma Drugs Market, by Administration Route, 2018-2023, 2024-2029 ($ millions)
Global Follicular Lymphoma Drugs Market Segment Percentages, by Administration Route, 2022 (%)
Injection
Oral
Global Follicular Lymphoma Drugs Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Follicular Lymphoma Drugs Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Follicular Lymphoma Drugs revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Follicular Lymphoma Drugs revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Roche
Gilead Sciences
TG Therapeutics
Bayer
Secura Bio
Epizyme
Eisai
Acrotech Biopharma
Teva
Eagle Pharmaceuticals
MundiPharma
Outline of Major Chapters:
Chapter 1: Introduces the definition of Follicular Lymphoma Drugs, market overview.
Chapter 2: Global Follicular Lymphoma Drugs market size in revenue.
Chapter 3: Detailed analysis of Follicular Lymphoma Drugs company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by administration route, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Follicular Lymphoma Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.